Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

NCT03640481 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

159

Enrollment

INDUSTRY

Sponsor class

Stopped The sponsor has decided to prematurely terminate the study due to the challenges encountered in recruiting adolescent participants. This decision was made without any safety concerns.

Conditions

Chronic Graft-versus-host-disease

Interventions

DRUG: Belumosudil (KD025)

Sponsor

Kadmon, a Sanofi Company